腹主动脉瘤修复术中非阿片类镇痛药物使用不足
单中心回顾性分析128例腹主动脉瘤修复患者,开放修复术后疼痛评分及阿片类药物处方率高于EVAR,非甾体抗炎药和对乙酰氨基酚使用极少;经皮EVAR较股动脉切开EVAR阿片用量更低,提示应优化非阿片类镇痛策略。
要点
- 开放修复术后阿片处方率77.3%,EVAR为35.0%,非阿片类药物使用率极低。
- 经皮EVAR住院阿片用量低于股动脉切开EVAR(17 vs 31.90 mg MME)。
- 硬膜外镇痛可降低开放修复术后疼痛评分(0.77 vs 3.50)。
核心结论
- 腹主动脉瘤修复患者以阿片类药物镇痛为主,非阿片类辅助治疗使用不足。
- 经皮EVAR和术中硬膜外镇痛可能减少阿片类药物总用量。
研究设计与样本
- 单中心回顾性研究,分析2010年1月1日至2018年1月1日期间128例腹主动脉瘤修复患者的围术期镇痛处方。
- 队列中21.8%(28例)行开放修复,78.12%(100例)行EVAR(46例经皮,54例股动脉切开)。
主要发现
- 开放修复术后疼痛评分高于EVAR(2.67±0.75 vs 0.96±0.19,P<0.01)。
- 开放修复术后阿片处方率高于EVAR(77.3% vs 35.0%,P<0.01)。
- 经皮EVAR与股动脉切开EVAR术后阿片处方率无差异(65.8% vs 80.1%,P=0.11)。
- 接受阿片类药物的患者中,开放修复平均MME为320.94 mg,EVAR为28.82 mg(P<0.01)。
- 经皮EVAR住院期间MME用量低于股动脉切开(17±3.52 vs 31.90±5.43 mg,P<0.01)。
关键数值与推荐
- 非甾体抗炎药在开放修复和EVAR术后使用率分别为8.3%和1.1%。
- 开放修复术后住院时间长于EVAR(9.82±1.27 vs 3.86±0.47天,P<0.01)。
- 经皮EVAR术后住院时间短于股动脉切开EVAR(3.2±0.26 vs 4.12±0.30天,P<0.01)。
临床怎么用
- 应重视腹主动脉瘤修复术后非阿片类镇痛药物的辅助使用。
- 经皮EVAR可能有助于减少住院期间阿片类药物用量。
- 硬膜外镇痛可作为开放修复术后疼痛管理的辅助手段。
局限性
- 单中心回顾性设计可能限制结论外推。
- 样本量较小(共128例),需更大规模研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: With increased focus on the opioid crisis, it was our goal to describe rates and risk factors for postoperative use of opioids in patients undergoing abdominal aortic aneurysm (AAA) repair as well as identify pain modalities that are underutilized. METHODS: We retrospectively analyzed perioperative analgesic prescriptions for endovascular (EVAR) and open AAA repair between January 1, 2010 and January 1, 2018. Patients' baseline opioid use, demographics, and medical comorbidities were obtained. The EVAR group was further subdivided into percutaneous (pEVAR) and cutdown (cEVAR) groups. Primary outcomes were postoperative and discharge pain medication prescriptions. Relative rates of opioid prescribing were obtained through the electronic medical record and normalized into morphine milligram equivalents (MMEs). RESULTS: Of the 128 patients analyzed in the entire cohort, 21.8% (n = 28) underwent open repair and 78.12% (n = 100) underwent EVAR (46 pEVAR, 54 cEVAR). As expected, open repair had increased postoperative pain reported compared to EVAR (2.67 ± 0.75 vs. 0.96 ± 0.19, P < 0.01). Adjunctive epidural reduced postoperative pain for open repair (0.77 ± 0.48 vs. 3.50 ± 0.96, P < 0.01). EVAR had less postoperative opioid prescriptions compared to open repair (35.0% vs. 77.3%, P < 0.01). In the endovascular group, there was no difference between postoperative opioid prescription based on access, pEVAR versus cEVAR (65.8% vs. 80.1%, P = 0.11). When stratifying patients by number of cutdowns, patients with bilateral cutdown as opposed to a single cutdown received more opioid prescriptions than pEVAR patients (84.44% vs. 65.8%, P = 0.036). Of those receiving opioids, the average MME for open repair was 320.94 mg compared to 28.82 mg for EVAR (P < 0.01). Those undergoing percutaneous repair had significantly less MME use during hospitalization compared to femoral cutdown (17 ± 3.52 vs. 31.90 ± 5.43 mg, P < 0.01). Nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen and ketorolac, were rarely used in the postoperative period for open or EVAR (8.3% vs 1.1%). Percutaneous EVAR patients reported less pain at discharge compared to cEVAR patients (0.18 ± 0.12 vs. 0.88 ± 0.29, P = 0.036). Open and EVAR had comparable low rates of NSAID and acetaminophen prescriptions at discharge. Open patients had longer postoperative length of stay compared to EVAR patients (9.82 ± 1.27 vs. 3.86 ± 0.47, P < 0.01). pEVAR had a shorter length of postoperative course compared to cEVAR (3.2 ± 0.26 vs. 4.12 ± 0.30, P < 0.01). Patients undergoing EVAR with use of pain medications amounting to <20 MME had a significantly shorter length of stay. CONCLUSIONS: This single institutional retrospective study evaluated pain prescription patterns for patients undergoing AAA repair. AAA patients are predominantly treated with opioid pain medications with few adjunctive therapies. Intraoperative epidural and pEVAR may aid in decreasing the total MME used; however, the total number of opioids prescribed is similar for pEVAR and cEVAR despite the difference in approach. Clinicians must consider alternative nonopioid based pain management strategies.
引用
- Phair J, Carnevale M, Levine D, et al. Underutilization of Nonopioid Pain Medication in Patients Undergoing Abdominal Aortic Aneurysm Repair. Ann Vasc Surg. 2020. PMID: 32442594. doi:10.1016/j.avsg.2020.04.068
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。